Piramal Pharma Crosses $1 Billion Revenue, Announces SBTi Approved Decarbonisation Plan

Piramal Pharma Limited (PPL) had a steady year in FY2025, crossing the $1 Billion revenue milestone with healthy growth in EBITDA and Net Profit. The company also announced its SBTi approved decarbonisation plan till FY2030. PPL's business comprises Piramal Pharma Solutions, an integrated Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care, one of the leading companies in Complex Hospital Generics (CHG) segment, and the Piramal Consumer Healthcare (PCH), which provides a range of over-the-counter healthcare and wellness products. The company is committed to sustainability, aligning with global benchmarks and embedding sustainability initiatives across its value chain.